Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ingeborg E. de Kruijff"'
Autor:
Ingeborg E. de Kruijff, Anieta M. Sieuwerts, Wendy Onstenk, Jaco Kraan, Marcel Smid, Mai N. Van, Michelle van der Vlugt-Daane, Esther Oomen-de Hoop, Ron H.J. Mathijssen, Martijn P. Lolkema, Ronald de Wit, Paul Hamberg, Hielke J. Meulenbeld, Aart Beeker, Geert-Jan Creemers, John W.M. Martens, Stefan Sleijfer
Publikováno v:
Cancers, Vol 11, Iss 8, p 1212 (2019)
(1) Background: Markers identifying which patients with metastatic, castration-resistant prostate cancer (mCRPC) will benefit from cabazitaxel therapy are currently lacking. Therefore, the aim of this study was to identify markers associated with out
Externí odkaz:
https://doaj.org/article/be6f8d4ca00441f7bda0749974eb8910
Autor:
Stefan Sleijfer, Paul Hamberg, Marcel Smid, Mieke Timmermans, Wendy Onstenk, John W.M. Martens, Jaco Kraan, Agnes Jager, Felix E. de Jongh, Ingeborg E. de Kruijff, Anieta M. Sieuwerts
Publikováno v:
International Journal of Cancer, 145(4), 1083-1089. Wiley-Liss Inc.
The androgen receptor (AR) has potential clinical relevance in metastatic breast cancer (mBC) since it might be a treatment target and has been associated with endocrine resistance. A minimal-invasive way to determine AR expression on metastatic tumo
Autor:
John van der Hoeven, Toine van der Heijden, Joost L. Boormans, Joep J. de Jong, Laurent M.C.L. Fossion, Rens Jacobs, Diederik M. Somford, Jaco Kraan, J.A. Witjes, Sjoerd O. Klaver, Ed te Slaa, Ingeborg E. de Kruijff, Peter de Vries, Nick Beije, Stefan Sleijfer, Carl Wijburg, Egbert R. Boevé, Harm H.E. van Melick, Ronald de Wit, John W.M. Martens
Publikováno v:
Journal of Clinical Oncology. 39:4523-4523
4523 Background: International guidelines for the treatment of non-metastatic muscle-invasive bladder cancer (MIBC) recommend neoadjuvant chemotherapy (NAC), which, however, is underutilized in practice. We hypothesized that the absence of circulatin
Autor:
Annemie Rutten, Steven Van Laere, Henrik Grönberg, Peter A. van Dam, Dirk Goossens, Daan De Maeseneer, Mattias Rantalainen, Willem Lybaert, Piet Ost, Steffi Oeyen, Jozef Ampe, Gert Van den Eynden, Jurgen Del Favero, Lien Heyrman, Michiel Strijbos, Barbara Brouwers, Anja Brouwer, Karen Fransis, Peter Van Oyen, Bram De Laere, Wim Demey, Lucien Hoekx, Stefan Sleijfer, Anders Ullén, Christophe Ghysel, Els Everaert, Prabhakar Rajan, Alain Bols, Nick Beije, Ingeborg E. de Kruijff, Jeffrey Yachnin, Markus Mayrhofer, Johan Lindberg, Valerie van Dam, Tom Whitington, Dirk Schrijvers, Luc Dirix
Publikováno v:
Clinical cancer research
CLINICAL CANCER RESEARCH
Clinical Cancer Research, 25(6), 1766-1773. American Association for Cancer Research Inc.
CLINICAL CANCER RESEARCH
Clinical Cancer Research, 25(6), 1766-1773. American Association for Cancer Research Inc.
Purpose: To infer the prognostic value of simultaneous androgen receptor (AR) and TP53 profiling in liquid biopsies from patients with metastatic castration-resistant prostate cancer (mCRPC) starting a new line of AR signaling inhibitors (ARSi). Expe
Autor:
John W.M. Martens, Michael A. den Bakker, Ingeborg E. de Kruijff, Marion E. Meijer-van Gelder, Renée Foekens, Antoinette Hollestelle, Stefan Sleijfer, Anita M. A. C. Trapman-Jansen, John A. Foekens, Marcel Smid, Esther Oomen-de Hoop, Carolien H.M. van Deurzen, Anna. M. Timmermans
Publikováno v:
Cancers
Cancers, 10(5):134. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers; Volume 10; Issue 5; Pages: 134
Cancers, 10(5):134. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers; Volume 10; Issue 5; Pages: 134
CD146, involved in epithelial-to-mesenchymal transition (EMT), might affect cancer aggressiveness. We here investigated the prevalence of CD146 expression in breast cancer subtypes, its relation to prognosis, the relation between CD146 and EMT and th
Autor:
Geert-Jan Creemers, Jaco Kraan, Marcel Smid, John W.M. Martens, Paul Hamberg, Stefan Sleijfer, Wendy Onstenk, Martijn P. Lolkema, Mai N. Van, Aart Beeker, Hielke J. Meulenbeld, Ronald de Wit, Michelle van der Vlugt-Daane, Ingeborg E. de Kruijff, Anieta M. Sieuwerts, Esther Oomen-de Hoop, Ron H.J. Mathijssen
Publikováno v:
Cancers
Volume 11
Issue 8
Cancers, Vol 11, Iss 8, p 1212 (2019)
Cancers, 11(8):1212. Multidisciplinary Digital Publishing Institute (MDPI)
Volume 11
Issue 8
Cancers, Vol 11, Iss 8, p 1212 (2019)
Cancers, 11(8):1212. Multidisciplinary Digital Publishing Institute (MDPI)
(1) Background: Markers identifying which patients with metastatic, castration-resistant prostate cancer (mCRPC) will benefit from cabazitaxel therapy are currently lacking. Therefore, the aim of this study was to identify markers associated with out
Autor:
Stefan Sleijfer, Wendy Onstenk, Anieta M. Sieuwerts, Mieke Timmermans, Marcel Smid, Felix E. de Jongh, Paul Hamberg, Agnes Jager, Ingeborg E. de Kruijff, John W.M. Martens
Publikováno v:
Journal of Clinical Oncology. 36:1087-1087
1087Background: The androgen receptor (AR) is of clinical relevance in metastatic breast cancer (mBC): AR has been associated with resistance to endocrine therapy and could be a potential target for therapy, especially in the triple negative (TN) sub